Table 2 Type of therapy by age group (most frequently used regimens)
Regimen | LOT1 (n = 889) | LOT ≥ 2 (n = 605) | ||||
|---|---|---|---|---|---|---|
|  | < 75 years | ≥ 75 years | p valuea,b | < 75 years | ≥ 75 years | p valuea,b |
|  | (n = 630) | (n = 259) |  | (n = 409) | (n = 196) |  |
Rituximab monotherapy, n (%) | 54 (8.6) | 50 (19.3) | <0.0001 | 52 (12.7) | 30 (15.3) | 0.3834 |
Combinations with rituximab, n (%) | 482 (76.5) | 139 (53.7) | <0.0001 | 243 (59.4) | 90 (45.92) | 0.0018 |
 Bendamustine/rituximab | 126 (20.0) | 61 (23.6) | 0.2377 | 125 (30.6) | 43 (21.9) | 0.0267 |
 Bendamustine/dexamethasone/rituximab | 5 (0.8) | 4 (1.5) |  | 5 (1.2) | 0 |  |
 Chlorambucil/rituximab | 0 | 4 (1.5) |  | 0 | 0 |  |
 Cyclophosphamide/rituximab | 0 | 0 |  | 0 | 3 (1.5) |  |
 Cyclophosphamide/fludarabine/dexamethasone/rituximab | 8 (1.3) | 0 |  | 0 | 0 |  |
 Cyclophosphamide/lenalidomide/rituximab | 0 | 0 |  | 4 (1.0) | 0 |  |
 Cyclophosphamide/pentostatin/rituximab | 21 (3.3) | 3 (1.2) |  | 13 (3.2) | 0 |  |
 Cyclophosphamide/vincristine/prednisone/rituximab | 14 (2.2) | 9 (3.5) |  | 8 (2.0) | 6 (3.1) |  |
 Fludarabine/cyclophosphamide/rituximab | 212 (33.7) | 18 (6.9) | <0.0001 | 41 (10.0) | 11 (5.6) | 0.0700 |
 Fludarabine/rituximab | 33 (5.2) | 22 (8.5) |  | 14 (3.4) | 11 (5.6) |  |
 Lenalidomide/rituximab | 10 (1.6) | 0 |  | 0 | 0 |  |
 Prednisone/rituximab | 0 | 4 (1.5) |  | 0 | 3 (1.5) |  |
 Investigational product/rituximab | 14 (2.2) | 0 |  | 0 | 0 |  |
Chemotherapy alone, n (%) | 65 (10.3) | 52 (20.1) | <0.0001 | 45 (11.0) | 50 (25.5) | <0.0001 |
 Bendamustine | 23 (3.7) | 8 (3.1) |  | 24 (5.9) | 21 (10.7) |  |
 Chlorambucil | 18 (2.9) | 22 (8.5) |  | 6 (1.5) | 12 (6.1) |  |
 Chlorambucil/prednisone | 0 | 12 (4.6) |  | 0 | 3 (1.5) |  |
 Cyclophosphamide | 0 | 4 (1.5) |  | 0 | 0 |  |
 Cyclophosphamide/fludarabine | 11 (1.7) | 0 |  | 0 | 2 (1.0) |  |
 Cyclophosphamide/vincristine/prednisone | 0 | 0 |  | 5 (1.2) | 0 |  |
 Fludarabine | 9 (1.4) | 0 |  | 5 (1.2) | 10 (5.1) |  |
 Other, n (%) | 14 (2.2) | 16 (6.2) | 0.0030 | 46 (11.3) | 18 (9.2) | 0.4400 |
 Alemtuzumab | 0 | 0 |  | 14 (3.4) | 6 (3.1) |  |
 Lenalidomide | 0 | 4 (1.5) |  | 0 | 0 |  |
 Ofatumumab | 0 | 0 |  | 17 (4.2) | 8 (4.1) |  |
 Investigational product | 6 (1.0) | 7 (2.7) |  | 13 (3.2) | 4 (2.0) |  |